The availability of weight loss drugs on the NHS doesn’t mean people can give up healthy lifestyles, Health Secretary Wes Streeting has warned. Experts believe drugs like Ozempic will play an ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Get the latest news on England plans to offer Mounjaro/Zepbound to obese individuals with multiple health conditions through ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.

Therefore, Lilly's ability to rapidly expand coverage with employers has gained significant traction, justifying its growth opportunities. Furthermore, Mounjaro has also continued to perform ...

Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes ...